2023
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Strober B, Ferris L, Callis Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 90: 82-90. PMID: 37739267, DOI: 10.1016/j.jaad.2023.08.097.Peer-Reviewed Original ResearchDermatology Life Quality Index scoresLife Quality Index scoresPsoriasis RegistryQuality Index scoresSevere psoriasisPsoriasis symptomsClear skinIndex scoreReal-world treatment effectivenessPrior biologic treatmentSevere plaque psoriasisInflammatory skin diseasePatient-reported outcomesEntire study populationReal-world effectivenessSignificant reductionPlaque psoriasisEligible adultsPatient adherenceBiologic treatmentActivity impairmentObservational studyStudy populationRisankizumabPsoriasis
2005
The treatment of psoriasis with etanercept.
Strober B. The treatment of psoriasis with etanercept. Seminars In Cutaneous Medicine And Surgery 2005, 24: 28-36. PMID: 15900796, DOI: 10.1016/j.sder.2005.01.003.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisTumor necrosis factor receptorTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsSigns of psoriasisAppropriate patient selectionPathogenesis of psoriasisNecrosis factor receptorEtanercept therapySevere psoriasisTolerability profilePatient selectionRisk ratioTNF-alphaAlpha inhibitorsClinical trialsEtanerceptProinflammatory activityPsoriasisBetter efficacyHigh dosesFactor receptorPatientsSignificant reductionTreatment